Rosacea
Conditions
Keywords
rosacea, Papulopustular Rosacea,erythema, dapsone
Brief summary
The purpose of this study is to evaluate the safety and effectiveness of ACZONE™ gel compared to placebo (inactive substance), MetroGel® and a combination of ACZONE™ gel and MetroGel® for the treatment of rosacea. ACZONE™ gel, 5% is a topical (applied to the skin) medication that is approved by the United States Food and Drug Administration (FDA) for the treatment of acne vulgaris in people 12 years and older. The use of ACZONE™ for the treatment of rosacea is investigational. An investigational use is one that is not approved by the FDA. Subjects will apply the study treatment for 12 weeks. Efficacy assessments will be performed at baseline and Weeks 2, 4, 8, and 12. Laboratory assessments will be conducted at baseline and Week, 2, 4 and 12.
Detailed description
Study Objective: •To evaluate the safety and preliminary efficacy of ACZONE in subjects with papulopustular rosacea Study Population: Approximately 400 male and female subjects will be enrolled at 27 study centers in the United States. Study Treatment: Subjects will be randomized to 1 of 5 treatment regimens. Subjects will receive study medication for 12 weeks. Study participation is 13 weeks (5 clinic visits and 1 telephone follow-up).
Interventions
DRUGVehicle control, 2x/day
DRUGACZONE (dapsone) Gel, 5%, 2x/day
DRUGACZONE (dapsone) Gel, 5%, 1x/day
DRUGMetroGel® (metronidazole gel), 1.0% 1x/day
DRUGACZONE (dapsone) Gel, 5%, 1x/day (AM) + MetroGel (metronidazole gel), 1.0%, 1x/day (PM)
Sponsors
Allergan
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
To be eligible for the study, subjects must fulfill all of the following criteria: 1. Men or women ≥18 years of age. 2. A diagnosis of papulopustular rosacea, with ≥10 inflammatory lesions (papules and/or pustules) above the mandibular line at baseline. 3. An Investigator Global Assessment (IGA) score ≥2 4. In good physical and mental health. 5. Signature of an approved informed consent form for the study and HIPAA authorization (if applicable). 6. Willingness to comply with the protocol.
Exclusion criteria
Subjects meeting any of the following criteria will be excluded from the study: 1. A skin examination reveals the presence of another skin disease and/or condition (excessive facial hair, excessive scarring, sunburn, or other disfigurement) located on the face that would confound the evaluation of the rosacea condition. 2. Current or past ocular rosacea, such as conjunctivitis, iritis, and keratitis, of sufficient severity to require topical or systemic antibiotics. 3. Treatment with topical antibiotics, topical steroids and other topical rosacea treatments on the face within 14 days of Baseline and throughout the study. 4. Treatment with systemic steroids within 30 days of Baseline and throughout the study. 5. Treatment with any systemic antibiotics within 30 days of Baseline and throughout the study. 6. Treatment with any systemic medication or therapy known to affect inflammatory responses within the 30 days prior to Baseline or throughout the study. 7. Treatment with topical retinoids within 30 days or systemic retinoids within 180 days of Baseline and throughout the study. 8. Treatment with physical modalities that could benefit rosacea are prohibited within 30 days of Baseline and throughout the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy: Percent change and change from baseline in inflammatory lesion counts; | — |
| Success rate, defined as proportion of subjects with a score of 0 or 1 and at least a 2 point improvement from baseline on the IGA scale; | — |
| Erythema & telangiectasia scores; | — |
| Lesion counts over time | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety: Adverse events and concomitant medications; Local symptom scores; Hematology and chemistry laboratory parameters; Vital signs | — |
| Other: Plasma dapsone concentrations | — |
Countries
United States
Outcome results
None listed